Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by BearDownAZ


ESPR

Clinical Development and Regulatory Update from 6/28/16

If one looks at the entire Clinical Development and Regulatory Update...

June 29, 2016

T.RVX

RE:RE:Esperion shares fell 27% to $11.75 in Tuesday night trading

ronrydell wrote: "Any implications here for RVX....My guess is that we...

June 29, 2016

T.RVX

RE:3 YEAR ANAVERSERY FROM F6/ INTERESTING/ THX F6

JK posted the following from F6:  "No mention on that day that -0...

June 28, 2016

T.RVX

RE:RE:Zenith Update Perspectives

Jk, Zenith Epigenetics Corp right now holds both technology assets (their...

June 20, 2016

T.RVX

RE:RE:RE:RE:RE:RE:Zenith call

George Zavoico was also one of the organizers (along with Don, Norman and...

June 20, 2016

T.RVX

RE:RE:RE:RE:RE:Zenith call

George Zavoico.

June 20, 2016

T.RVX

RE:Zenith Update Perspectives

Nice summary Toniv. I think your 93 billion as meant to be 9.3 billion. I...

June 20, 2016

T.RVX

RE:RVX management

Excellent post Toniv. Perfect for Agoracom too BTW. Justified, substantiated...

June 18, 2016

T.RVX

New Zealand Renal Phase 1 Trial with RVX-208

The Phase 1 New Zealand Renal Trial with RVX-208 (aka apabetalone, RVX000222)...

June 17, 2016

T.RVX

RE:RE:Zenith Announces Dosing of First Patient in Phase 1 C Trial

It is standard practive when the current first line therapy is enzalutamide...

June 16, 2016

V.BTI.H

RE:RE:today's presentation and inauspicious trading

Craighenry wrote "Why wasn't RH there?" at ASCO. Most likely...

June 9, 2016

V.BTI.H

Q2 2016 slides from BIO 2016 now available

Q2 2016 slide deck from the BiOasis presentation at BIO International 2016 in...

June 8, 2016

V.BTI.H

RE:RE:BIOAF VOLUME UP TO 25 k

Hopefully it will be a sunny day in San Francisco on Tuesday next week at BIO...

June 3, 2016

T.RVX

RE:RE:Resverlogix Announces Lead Drug Apabetalone Publication

We discussed this paper/study on the RVX hub on Agoracom last week on May...

June 2, 2016

T.RVX

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:BioWorld-Interesting article

G1945V, Provenge is not a cure for mCRPC. It has no effect on time to...

May 19, 2016

T.RVX

RE:RE:RE:RE:RE:RE:RE:RE:BioWorld-Interesting article

G1945V, Dont' get excited about seeing "ClinicalTrials.gov...

May 19, 2016

T.RVX

RE:RE:RE:RE:RE:BioWorld-Interesting article

$93,000 gets you a 4.1 month improvement in median survival. From the ...

May 18, 2016

T.RVX

RE:RE:BioWorld-Interesting article

This article on Provenge from www.cancer.org should answer your question...

May 18, 2016

V.BTI.H

RE:9th World Drug Delivery Summit

In addition to the June 30th 9th World Drug Delivery Summit talk that...

May 13, 2016

T.RVX

RE:RE:RE:RE:UPDATED REPORT-Research Analyst Marcel Wijma MSc May11/16

I agree with Archman. You can also see for yourself here: http://www...

May 13, 2016